eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 74
Review paper

Prognostic significance of PD-L1 expression in pancreatic cancer: evidence from an updated meta-analysis

Chenchen Liu
Lijuan Fan
Qian Wu
Yingjie Shi
Xuan Sun

Department of Gastroenterology, Affiliated Hospital of Putian University, Putian, Fujian, P.R. China
Ophthalmology Department, Affiliated Hospital of Putian University, Putian, Fujian, P.R. China
Department of of Infectious Diseases, Jining No. 1 People’s Hospital, Jining, Shandong Province, P.R. China
Department of Neonatology, Jining No. 1 People’s Hospital, Jining, Shandong Province, P.R. China
Pol J Pathol 2023; 74 (3): 151-160
Online publish date: 2023/10/25
View full text Get citation
PlumX metrics:
Recent studies revealed that programmed cell death ligand 1 (PD-L1) expression was associated with unfavorable prognosis in various solid tumors, but its clinical relevance for pancreatic cancer has not yet been well established. This meta-analysis summarizes the potential prognostic value of PD-L1 in pancreatic cancer. A quantitative meta-analysis was performed by a systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane library, Scopus and Ovid for eligible studies on the prognostic significance of PD-L1 in pancreatic cancer patients. Pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated to evaluate the strength of the link between PD-L1 expression and clinical prognosis of patients. Seventeen eligible studies with 2669 patients were included in our study. A significant association was observed between PD-L1 abundance and poor overall survival (OS) of patients with pancreatic cancers, with a pooled hazard ratio (HR) of 1.902, 95% CI: 1.657-2.184. Sensitivity analysis confirmed the reliability of our results. Subgroup analysis shows that differences in regions and detection methods of PD-L1 did not change the overall predictive value of PD-L1 for poor prognosis in pancreatic cancer patients. This meta-analysis indicated that the expression of PD-L1 is associated with a worse OS in pancreatic cancer patients. Additionally, PD-L1 may act as a potential parameter for predicting poor prognosis and thus providing a promising target for anticancer therapy in pancreatic cancer.

PD-L1, pancreatic cancer, prognosis, meta-analysis

Quick links
© 2023 Termedia Sp. z o.o.
Developed by Bentus.